Guardant Health, Inc. $GH Shares Bought by Federated Hermes Inc.

Federated Hermes Inc. grew its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 21.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,776,369 shares of the company’s stock after purchasing an additional 310,931 shares during the quarter. Federated Hermes Inc. owned approximately 1.42% of Guardant Health worth $110,988,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in GH. Signaturefd LLC lifted its stake in Guardant Health by 50.5% in the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after buying an additional 213 shares during the last quarter. IFP Advisors Inc increased its holdings in shares of Guardant Health by 120.1% in the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after acquiring an additional 334 shares during the period. Main Management ETF Advisors LLC lifted its position in Guardant Health by 1.7% in the 2nd quarter. Main Management ETF Advisors LLC now owns 21,257 shares of the company’s stock valued at $1,106,000 after purchasing an additional 348 shares during the last quarter. CWM LLC boosted its stake in Guardant Health by 21.6% during the 3rd quarter. CWM LLC now owns 2,020 shares of the company’s stock valued at $126,000 after purchasing an additional 359 shares during the period. Finally, F m Investments LLC grew its position in Guardant Health by 1.2% in the 2nd quarter. F m Investments LLC now owns 39,099 shares of the company’s stock worth $2,035,000 after purchasing an additional 471 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

GH opened at $109.73 on Thursday. The company has a market capitalization of $13.83 billion, a PE ratio of -34.18 and a beta of 1.58. The stock’s fifty day moving average is $106.19 and its 200-day moving average is $78.94. Guardant Health, Inc. has a one year low of $34.88 and a one year high of $120.74.

Guardant Health (NASDAQ:GH) last released its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09. During the same period last year, the business earned ($0.88) EPS. Guardant Health’s revenue was up 38.5% compared to the same quarter last year. On average, equities research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on GH. Piper Sandler lifted their price target on Guardant Health from $60.00 to $90.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. JPMorgan Chase & Co. raised their target price on Guardant Health from $90.00 to $120.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Leerink Partners boosted their price target on Guardant Health from $115.00 to $155.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Mizuho set a $135.00 price target on Guardant Health in a research note on Friday, January 9th. Finally, Guggenheim lifted their price objective on shares of Guardant Health from $115.00 to $135.00 and gave the company a “buy” rating in a research note on Monday. Twenty-one research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Guardant Health has an average rating of “Moderate Buy” and a consensus price target of $103.76.

Insider Activity

In other Guardant Health news, CEO Amirali Talasaz sold 100,000 shares of Guardant Health stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $105.05, for a total value of $10,505,000.00. Following the transaction, the chief executive officer owned 168,223 shares in the company, valued at approximately $17,671,826.15. The trade was a 37.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Terilyn J. Monroe sold 8,571 shares of the stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total value of $977,865.39. Following the sale, the insider owned 20,990 shares of the company’s stock, valued at $2,394,749.10. This trade represents a 28.99% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 445,123 shares of company stock valued at $46,600,702 in the last ninety days. 6.10% of the stock is owned by company insiders.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.